Patents by Inventor Takumitsu MACHIDA

Takumitsu MACHIDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING LSD1-RELATED DISEASES AND DISORDERS WITH LSD1 INHIBITORS
    Publication number: 20220387384
    Abstract: A method of treating an LSD1-related disease or disorder in a patient in need, the method comprising administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising daily dosing for one week or two weeks, followed by a resting period of one week.
    Type: Application
    Filed: November 13, 2020
    Publication date: December 8, 2022
    Inventors: Hiroko HITOTSUMACHI, Takumitsu MACHIDA, Masaki YAMADA, Harold KEER, Aram OGANESIAN
  • 5H-pyrrolo[2,3-D]pyrimidin-6(7H)-one derivative
    Patent number: 10538528
    Abstract: The invention of the present application provides a compound represented by Formula (I) or a salt thereof, which exhibits an inhibitory activity against at least one kinase selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase and/or a cell proliferation inhibiting effect and is useful as a prophylactic and/or therapeutic agent for diseases associated with the above-mentioned kinases, particularly cancer.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 21, 2020
    Assignee: Taiho Pahrmaceutical Co., Ltd.
    Inventors: Tetsuya Sugimoto, Toshihiro Sakamoto, Fuyuki Yamamoto, Yu Kobayakawa, Naoki Egashira, Koji Ichikawa, Takumitsu Machida
  • NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE
    Publication number: 20190292190
    Abstract: The invention of the present application provides a compound represented by Formula (I) or a salt thereof, which exhibits an inhibitory activity against at least one kinase selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase and/or a cell proliferation inhibiting effect and is useful as a prophylactic and/or therapeutic agent for diseases associated with the above-mentioned kinases, particularly cancer.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 26, 2019
    Applicant: Taiho Pharmaceutical Co., Ltd.
    Inventors: Tetsuya SUGIMOTO, Toshihiro SAKAMOTO, Fuyuki YAMAMOTO, Yu KOBAYAKAWA, Naoki EGASHIRA, Koji ICHIKAWA, Takumitsu MACHIDA